---
title: "Weekly Recap | Alpha Tau Medical +2.66%, IMPACT enrolment complete"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/298097155.md"
description: "Alpha Tau Medical (DRTS) rose 2.66% this week to close at $15.03, comfortably ahead of the S&P 500’s +0.09%, an outperformance of about 2.57 percentage points. The stock started weak: Monday (Aug 31) opened higher but slid to $14.11, and Tuesday (Sep 1) briefly touched the week’s low at $13.65 before settling at $13.96. From Wednesday it pushed higher, peaking at $15.17 on Friday (Sep 4) and closing at $15.03. Weekly amplitude was 10.35%, with average daily volume around 1."
datetime: "2026-09-05T06:41:24.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/298097155.md)
  - [en](https://longbridge.com/en/news/298097155.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/298097155.md)
generator: "portal-rs"
---

# Weekly Recap | Alpha Tau Medical +2.66%, IMPACT enrolment complete

## The Week

Alpha Tau Medical (DRTS) rose 2.66% this week to close at $15.03, comfortably ahead of the S&P 500’s +0.09%, an outperformance of about 2.57 percentage points. The stock started weak: Monday (Aug 31) opened higher but slid to $14.11, and Tuesday (Sep 1) briefly touched the week’s low at $13.65 before settling at $13.96. From Wednesday it pushed higher, peaking at $15.17 on Friday (Sep 4) and closing at $15.03. Weekly amplitude was 10.35%, with average daily volume around 1.07m shares, about 78% above the 60-day median, pointing to a pickup in turnover.

## Key Events

The week was anchored by the completion of enrolment in the 48-patient IMPACT pancreatic cancer Alpha DaRT pilot study, announced on Monday (Aug 31). On Wednesday (Sep 2), the company confirmed that CFO Levy would join a fireside chat at the H.C. Wainwright global investor conference. Two articles on Saturday (Sep 5) added to the narrative: one noted the stock touching a 1-year high, the other asked whether the IMPACT enrolment milestone is reshaping the investment case. No major regulatory or partnership updates appeared this week; the story was largely clinical progress plus investor communications.

## Analyst Ratings

Five brokers cover the stock: three rate it buy, one overweight, and one hold, with no underweight or sell calls. The consensus rating is buy, with a consensus target of $17, roughly 13.1% above the $15.03 close. The target range is wide, from $8 to $30, reflecting real dispersion in views. Within the medical devices industry, the stock ranks 53rd out of 142 names, in the upper-middle of the group.

## The Week Ahead

No company earnings are scheduled. On the macro front, the US NFIB small business optimism index lands on Tuesday (Sep 8). Thursday (Sep 10) is busier: initial jobless claims, final demand PPI and core PPI, existing home sales, wholesale sales, and the 10-year Treasury auction’s high yield and bid-to-cover ratio. For a clinical-stage medtech name, the key thing to watch is whether management follows up on the IMPACT enrolment with any signal on data readouts or timelines.

## In Short

This week’s tension sits between clinical momentum and valuation divergence. The completion of IMPACT pancreatic cancer enrolment was the main company event, yet the wide $8-to-$30 target range shows how split the market remains on long-term value. Latest-session flows were mixed: smaller-size money on the bid, large-lot money on the offer. The next test is the cadence of IMPACT data and whether investor conferences bring a firmer timeline.

*This article is generated by LongbridgeAI from market data, for information only and not investment advice.*

### Related Stocks

- [DRTS.US](https://longbridge.com/en/quote/DRTS.US.md)

## Related News & Research

- [Alpha Tau Medical Ltd. (TASE:DRTS) Posts Strong Early Cancer Trial Signals; Key Readouts Ahead](https://longbridge.com/en/news/299216743.md)
- [Alpha Tau completes enrollment in 48-patient IMPACT pancreatic cancer Alpha DaRT pilot study](https://longbridge.com/en/news/297513505.md)
- [UBS CEO Ermotti warns against harsh capital rules ahead of vote](https://longbridge.com/en/news/299565274.md)
- [HBM Healthcare Investments says Electra Therapeutics IPO raises USD 350 million](https://longbridge.com/en/news/299591426.md)
- [3 U.S. Life Insurance Stocks Built For Higher Interest Rates](https://longbridge.com/en/news/299566968.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**